We are focused on expanding patient access to biologic drugs by delivering less expensive, equally effective biosimilars.
Valorum finds high quality assets to develop and commercialize, with a focus on markets that are currently underserved. Our pipeline is focused on high-value and/or first-to-market biosimilar drugs for ophthalmology and oncology indications.
Leadership with experience at top companies across pharma and drug distribution
Valorum looks for clinically proven assets that are being developed globally and have a high probability of success. We aim to expedite the development and commercialization of assets through the expertise of our team members, who possess US commercial and clinical development experience. The Valorum team has led development of small and large molecule assets from preclinical studies through to global Phase 3 trials and commercialization.